Mass Tort brief
Mass Tort: Corporate Restructuring and Bellwether Battles
L'Oréal explores bankruptcy shields over hair relaxer cancer claims as multi-billion dollar class settlements hit legal roadblocks in state and federal courts.
Mass Tort
L'Oréal hired restructuring counsel as hair relaxer lawsuits topped 12,380 — exploring Chapter 11 maneuvers to shield its core consumer business from ruinous verdicts.
BackgroundThe federal hair relaxer multidistrict litigation consolidates thousands of claims alleging endocrine-disrupting chemicals in straightening cosmetics cause hormone-sensitive cancers. Corporate defendants frequently consider restructuring or bankruptcy spin-offs when mass injury claims threaten operating balance sheets.
- Federal multidistrict proceedings centralized in Illinois encompass more than 12,380 active cancer injury cases filed against L'Oréal brands, creating substantial uncapped balance sheet exposure.
- The strategic restructuring review follows a lawsuit by the Arizona Attorney General accusing the cosmetics company of concealing chemical cancer risks from consumers for decades.
- Plaintiffs' attorneys warned that attempting to ring-fence chemical liabilities through Texas-two-step bankruptcies will trigger aggressive court challenges, citing recent appellate decisions rejecting divisional mergers.
Mass Tort
Sun and Taro agreed to pay $200M to exit generic price-fixing litigation — eliminating their trial risk while increasing pressure on remaining generic drugmakers to settle.
BackgroundIn re Generic Pharmaceuticals Pricing Antitrust Litigation concentrates claims accusing generic drug manufacturers of coordinating market allocation and price fixing. Regulators and private buyers alleged manufacturers orchestrated coordinated price hikes across dozens of essential prescription medications over a decade.
- The agreement establishes a $200M cash fund to resolve end-payer damages while formally extinguishing related antitrust class claims against both Sun and Taro.
- Settlement administrators will distribute financial recoveries directly to union health welfare funds and individual consumers who overpaid for routine generic prescriptions.
- The resolution closes end-payer liability for the two settling manufacturers, leaving dozens of unaligned generic pharmaceutical competitors to face impending federal trials alone.
Mass Tort
Bayer's $7.25B Roundup deal stalled over objections that it binds future cancer victims — leaving 61,000 active lawsuits hanging over the company.
BackgroundBayer acquired agrochemical giant Monsanto in 2018 for $63B, inheriting tens of thousands of product liability lawsuits alleging Roundup weedkiller causes non-Hodgkin lymphoma. The German conglomerate has repeatedly attempted to craft comprehensive class settlements to resolve personal injury claims and cap future corporate exposure.
- State Judge Timothy Boyer took final settlement approval under advisement after objectors argued the agreement's claims cutoff unfairly strips future cancer patients of their trial rights.
- More than 61,000 active Roundup injury lawsuits remain pending across state courts alongside 1,104 cases in California federal proceedings, preventing Bayer from putting litigation behind it.
- Agricultural chemical trade groups continue lobbying Congress for federal statutory preemption shields, attempting to bar state-level pesticide failure-to-warn claims through upcoming farm legislation.
Mass Tort
A federal judge blocked J&J depositions in the McKinsey opioid MDL — shielding the settled drugmaker from expansive third-party discovery that could unravel completed settlements.
BackgroundMultidistrict litigation against McKinsey alleges the consulting firm designed aggressive marketing playbooks to help pharmaceutical manufacturers maximize opioid distributions during the addiction epidemic. Johnson & Johnson previously resolved national opioid liabilities through a comprehensive $5B nationwide master settlement agreement with states and municipalities.
- U.S. Magistrate Judge Sallie Kim ruled that compelling J&J representatives to testify regarding 30 years of historical marketing exceeded reasonable third-party discovery limits under federal civil rules.
- Plaintiffs sought corporate testimony regarding how McKinsey consultants advised J&J on expanding fentanyl patch and painkiller distributions, hoping to establish consulting liability through client interactions.
- The protective order insulates J&J from burdensome witness depositions in litigation where it is no longer an active named defendant, preserving its final settlement boundaries.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
